AI-generated summary
The authors compared three weeks of transcranial photobiomodulation with no intervention in 36 older adults with mild cognitive impairment. They report improvements in the treatment group in visual working memory, anti-saccade latency, Montreal Cognitive Assessment scores, Shape Trail Test B completion time and depressive symptoms, which they describe as preliminary evidence.
- Participants
- 36
- Who or what was studied
- Community-dwelling older adults with mild cognitive impairment
- Limits stated in the abstract
- The abstract describes the findings as preliminary, and the control group was small (n = 11) compared with the treatment group (n = 25).
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Mild cognitive impairment, Photobiomodulation, Control group, Montreal Cognitive Assessment, Near-infrared. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.